These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Study of the protein profile of the Adélé tribe of Togo]. Tété-Bénissan AC; Duriez P; Parra HJ Sante; 2000; 10(4):261-6. PubMed ID: 11111244 [TBL] [Abstract][Full Text] [Related]
9. [Humoral and cellular immunity in patients with left- and right-sided intracerebral tumors]. Lisianyĭ NI; Markova OV; Prikhodchenko IA; Primushko LI Zh Vopr Neirokhir Im N N Burdenko; 1989; (2):33-5. PubMed ID: 2787570 [TBL] [Abstract][Full Text] [Related]
10. Individual serum proteins and acute phase reactants in monoclonal immunoglobulinopathies (a study in patients with IgG myeloma). Wiedermann D; Widermann B; Cídl K; Kodousková V Neoplasma; 1978; 25(2):189-96. PubMed ID: 643123 [TBL] [Abstract][Full Text] [Related]
11. Aluminum concentrations in serum of patients with intracranial tumors. Philipov P; Tzatchev K Zentralbl Neurochir; 1993; 54(3):148-50. PubMed ID: 8237170 [TBL] [Abstract][Full Text] [Related]
12. Effects of smoking and age on serum levels of immune-reactive proteins altered in cancer patients. Weiss JF; Wolf GT; Edwards BK; Chretien PB Cancer Detect Prev; 1981; 4(1-4):211-7. PubMed ID: 6984657 [TBL] [Abstract][Full Text] [Related]
13. Serum immunoglobulin and acute phase protein concentrations in pulmonary tuberculosis patients in Singapore. Wong CT; Saha N Trop Geogr Med; 1989 Jul; 41(3):218-21. PubMed ID: 2480678 [TBL] [Abstract][Full Text] [Related]
14. [The features of the brain immune system in brain neoplasms]. Starchenko AA; Khil'ko VA; Komarets SA; Shulev IuA; Ivanteeva EP; Bikmullin VN; Prilukova TI Zh Vopr Neirokhir Im N N Burdenko; 2002; (4):22-6; discussion 26-7. PubMed ID: 12608143 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson WD; Basten A; Hargrave JC Int J Lepr Other Mycobact Dis; 1987 Jun; 55(2):277-85. PubMed ID: 2439620 [TBL] [Abstract][Full Text] [Related]
16. [Immunological study of glioma. (2) Changes of immunological responses during treatment]. Sobue H; Tanimura K; Terabayashi T; Minagawa M; Inoue K No To Shinkei; 1976 Jan; 28(1):87-93. PubMed ID: 194609 [No Abstract] [Full Text] [Related]
17. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Braun DP; Penn RD; Flannery AM; Harris JE Neurosurgery; 1982 Feb; 10(2):203-9. PubMed ID: 6280097 [TBL] [Abstract][Full Text] [Related]
18. [Characteristics and immunologic changes in patients with malignant brain tumors]. Khonina NA; Tsentner MI; Leplina OIu; Tikhonova MA; Stupak VV; Nikonov SD; Chërnykh ER; Ostanin AA Vopr Onkol; 2002; 48(2):196-201. PubMed ID: 12227068 [TBL] [Abstract][Full Text] [Related]
19. [Antigen-specific immunotherapy as a component of combined therapy for malignant brain tumors]. Ostanin AA; Tsentner MI; Khonina NA; Leplina OIu; Shevela EIa; Nikonov SD; Stupak VV; Chërnykh ER Vopr Onkol; 2003; 49(2):170-5. PubMed ID: 12785199 [TBL] [Abstract][Full Text] [Related]
20. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Rempel SA; Dudas S; Ge S; Gutiérrez JA Clin Cancer Res; 2000 Jan; 6(1):102-11. PubMed ID: 10656438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]